Notably, studies in recent years have shown that the glucose-sensing transcription factor MondoA/carbohydrate response element-binding protein (ChREBP) is emerging as a potential target to treat T2D [11,12,13,14]. The gene discussed is MLXIPL; the disease is type 2 diabetes mellitus.